Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations

BACKGROUND: CDKN2A and TP53 mutations are recurrent events in melanoma, occurring in 13.3% and 15.1% of cases respectively and are associated with poorer outcomes. It is unclear what effect CDKN2A and TP53 mutations have on the clinical outcomes of patients treated with checkpoint inhibitors. METHOD...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Main Authors: DeLeon, Thomas T., Almquist, Daniel R., Kipp, Benjamin R., Langlais, Blake T., Mangold, Aaron, Winters, Jennifer L., Kosiorek, Heidi E., Joseph, Richard W., Dronca, Roxana S., Block, Matthew S., McWilliams, Robert R., Kottschade, Lisa A., Rumilla, Kandelaria M., Voss, Jesse S., Seetharam, Mahesh, Sekulic, Aleksandar, Markovic, Svetomir N., Bryce, Alan H.
Formato: Artigo
Idioma:Inglês
Publicado: Public Library of Science 2020
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7083309/
https://ncbi.nlm.nih.gov/pubmed/32196516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0230306
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares